Clinical Trials at Henry Ford Health System
As of August 2026, 65 paid clinical trials are recruiting at Henry Ford Health System, located at 2799 W GRAND BLVD, DETROIT, MI 48202-2608, phone (313) 916-2600 in Detroit, Michigan. Active studies at this site cover conditions such as Endometrial Cancer, Advanced Solid Tumor and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Detroit
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
66 clinical trials at Henry Ford Health System
·Clear filters·OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Radioembolization Versus External Radiation Therapy
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
National Liver Cancer Screening Trial
The Fourth Left Atrial Appendage Occlusion Study
Common conditions studied in Detroit
- Endometrial Cancer (14 active studies)
- Advanced Solid Tumor (13 active studies)
- Breast Cancer (13 active studies)
- Heart Failure (13 active studies)
- Multiple Myeloma (12 active studies)
- Ovarian Cancer (12 active studies)
Leading research sponsors in Detroit
- Henry Ford Health System
- National Cancer Institute (NCI)
- AstraZeneca
- Wayne State University
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in Detroit?
There are approximately 718 recruiting clinical trials in Detroit, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Detroit pay participants?
Most recruiting trials in Detroit compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Detroit?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Detroit?
The most common conditions under active study in Detroit include Endometrial Cancer (14), Advanced Solid Tumor (13), Breast Cancer (13), Heart Failure (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Detroit?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Detroit on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Detroit?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Detroit?
Recruiting research sites in Detroit include Henry Ford Hospital, Karmanos Cancer Institute, Henry Ford Health System, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Detroit right now?
The largest active categories in Detroit are Cancer & tumors (305), Cardiovascular (51), Neurology & pain (26). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Henry Ford Health System?
Henry Ford Health System is located at 2799 W GRAND BLVD, DETROIT, MI 48202-2608. Use the Google Maps link in the intro above to get directions.
How do I contact Henry Ford Health System?
You can reach Henry Ford Health System by phone at (313) 916-2600. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.